Skip to main content
SpringerLink
Log in

Connective Tissue Disease

  • Chapter
  • First Online:
Severe Skin Diseases in Children

  • 1088 Accesses

Abstract

Children with connective tissue disease may frequently require treatment other than topical therapy for their disorder. This chapter will cover those connective tissue diseases with cutaneous features and that may require consideration for systemic treatment—in particular, cutaneous and systemic lupus erythematosus, morphea, systemic sclerosis, and juvenile dermatomyositis. Clinical presentations will be briefly reviewed, with a focus on recognizing disease subtypes or clinical scenarios that deserve stronger consideration for systemic therapy. In addition, the dermatologist’s role in providing adjunctive therapy to control cutaneous manifestations is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACLE:

Acute cutaneous lupus erythematosus

CCLE:

Chronic cutaneous lupus erythematosus

CLE:

Cutaneous lupus erythematosus

CTD:

Connective tissue disease

dcSSc:

Diffuse cutaneous systemic sclerosis

DLE:

Discoid lupus erythematosus

JDM:

Juvenile dermatomyositis

jSSc:

Juvenile systemic sclerosis

lcSSc:

Limited cutaneous systemic sclerosis

NLE:

Neonatal lupus erythematosus

pSLE:

Pediatric systemic lupus erythematosus

RP:

Raynaud’s phenomenon

SCLE:

Subacute lupus erythematosus

SLE:

Systemic lupus erythematosus

References

  1. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. Arch Dermatol. 2009;145(3):249–53. doi:10.1001/archdermatol.2009.21. 145/3/249 [pii].

    PubMed  Google Scholar 

  2. Dickey BZ, Holland KE, Drolet BA, Galbraith SS, Lyon VB, Siegel DH, Chiu YE. Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre. Br J Dermatol. 2013.

    Google Scholar 

  3. Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus. 2010;19(9):1050–70. doi:10.1177/0961203310370048. 19/9/1050 [pii].

    PubMed  CAS  Google Scholar 

  4. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006;5(2):160–4. doi:10.1016/j.autrev.2005.10.003. S1568-9972(05)00178-3 [pii].

    PubMed  Google Scholar 

  5. Pramatarov KD. Chronic cutaneous lupus erythematosus – clinical spectrum. Clin Dermatol. 2004;22(2):113–20. doi:10.1016/j.clindermatol.2003.12.016. S0738081X03001366 [pii].

    PubMed  Google Scholar 

  6. Van Gysel D, de Waard-van der Spek FB, Oranje AP. Childhood discoid lupus erythematosus: report of five new cases and review of the literature. J Eur Acad Dermatol Venereol. 2002;16(2):143–7.

    PubMed  Google Scholar 

  7. Moises-Alfaro C, Berron-Perez R, Carrasco-Daza D, Gutierrez-Castrellon P, Ruiz-Maldonado R. Discoid lupus erythematosus in children: clinical, histopathologic, and follow-up features in 27 cases. Pediatr Dermatol. 2003;20(2):103–7. 20201 [pii].

    PubMed  Google Scholar 

  8. Sampaio MC, de Oliveira ZN, Machado MC, dos Reis VM, Vilela MA. Discoid lupus erythematosus in children – a retrospective study of 34 patients. Pediatr Dermatol. 2008;25(2):163–7. doi:10.1111/j.1525-1470.2008.00625.x. PDE625 [pii].

    PubMed  Google Scholar 

  9. Nico MM, Vilela MA, Rivitti EA, Lourenco SV. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol. 2008;18(4):376–81. doi:10.1684/ejd.2008.0388. ejd.2008.0388 [pii].

    PubMed  Google Scholar 

  10. James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, Walker C, Dennis GJ, Merrill JT, Harley JB. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16(6):401–9. doi:10.1177/0961203307078579. 16/6/401 [pii].

    PubMed  CAS  Google Scholar 

  11. Schmidt E, Tony HP, Brocker EB, Kneitz C. Sun-induced life-threatening lupus nephritis. Ann N Y Acad Sci. 2007;1108:35–40.

    PubMed  CAS  Google Scholar 

  12. Stern RS, Docken W. An exacerbation of SLE after visiting a tanning salon. JAMA. 1986;255(22):3120.

    PubMed  CAS  Google Scholar 

  13. Kuhn A, Sonntag M, Richter-Hintz D, Oslislo C, Megahed M, Ruzicka T, Lehmann P. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol. 2001;45(1):86–95. doi:10.1067/mjd.2001.114589. S0190-9622(01)91037-0 [pii].

    PubMed  CAS  Google Scholar 

  14. Klein RS, Sayre RM, Dowdy JC, Werth VP. The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus. Autoimmun Rev. 2009;8(4):320–4. doi:10.1016/j.autrev.2008.10.003. S1568-9972(08)00204-8 [pii].

    PubMed  Google Scholar 

  15. Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, Lehmann P, Metze D, Ruzicka T. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011;64(1):37–48. doi:10.1016/j.jaad.2009.12.053. S0190-9622(10)00009-5 [pii].

    PubMed  CAS  Google Scholar 

  16. Heine G, Lahl A, Muller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol. 2010;163(4):863–5. doi:10.1111/j.1365-2133.2010.09948.x.

    PubMed  CAS  Google Scholar 

  17. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;(4):CD002954. doi:10.1002/14651858.CD002954.pub2.

  18. Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol. 2007;156(1):191–2. doi:10.1111/j.1365-2133.2006.07595.x. BJD7595 [pii].

    PubMed  CAS  Google Scholar 

  19. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34(7):776–80. doi:10.1111/j.1365-2230.2008.03138.x. CED3138 [pii].

    PubMed  CAS  Google Scholar 

  20. Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol. 2010;35(1):27–30. doi:10.1111/j.1365-2230.2009.03351.x. CED3351 [pii].

    PubMed  CAS  Google Scholar 

  21. Jemec GB, Ullman S, Goodfield M, Bygum A, Olesen AB, Berth-Jones J, Nyberg F, Cramers M, Faergemann J, Andersen P, Kuhn A, Ruzicka T. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol. 2009;161(6):1365–70. doi:10.1111/j.1365-2133.2009.09330.x. BJD9330 [pii].

    PubMed  CAS  Google Scholar 

  22. Gerdsen R, Wenzel J, Uerlich M, Bieber T, Petrow W. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology. 2002;205(4):416–8. 66428 [pii].

    PubMed  Google Scholar 

  23. Gul U, Gonul M, Cakmak SK, Kilic A, Demiriz M. A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. Adv Ther. 2006;23(5):787–92. 543 [pii].

    PubMed  Google Scholar 

  24. Burnett TJ, English 3rd JC, Ferris LK. Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses. J Drugs Dermatol. 2010;9(8):1022–4.

    PubMed  Google Scholar 

  25. Chan MP, Zimarowski MJ. Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases. Am J Dermatopathol. 2011;33(5):523–7. doi:10.1097/DAD.0b013e3181f2bf9e.

    PubMed  Google Scholar 

  26. Barr KL, Konia TH, Fung MA. Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall. J Cutan Pathol. 2011;38(4):346–50. doi:10.1111/j.1600-0560.2010.01592.x. CUP1592 [pii].

    PubMed  Google Scholar 

  27. Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol. 1999;41(6):1049–50. S0190-9622(99)70278-1 [pii].

    PubMed  CAS  Google Scholar 

  28. Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis. 1991;47(5):351–5.

    PubMed  CAS  Google Scholar 

  29. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20(4):160–74. doi:10.1111/j.1529-8019.2007.00131.x. DTH131 [pii].

    PubMed  Google Scholar 

  30. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127(5):513–8.

    PubMed  CAS  Google Scholar 

  31. Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3073–8. doi:10.1002/art.21358.

    PubMed  CAS  Google Scholar 

  32. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147(11):1261–7. doi:10.1001/archdermatol.2011.191. archdermatol.2011.191 [pii].

    PubMed  CAS  Google Scholar 

  33. Cavazzana I, Sala R, Bazzani C, Ceribelli A, Zane C, Cattaneo R, Tincani A, Calzavara-Pinton PG, Franceschini F. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus. 2009;18(8):735–9. doi:10.1177/0961203308101714. 18/8/735 [pii].

    PubMed  CAS  Google Scholar 

  34. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011;65(6):e195–213. doi:10.1016/j.jaad.2010.06.017. S0190-9622(10)00698-5 [pii].

    PubMed  Google Scholar 

  35. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med. 1982;97(2):165–70.

    PubMed  CAS  Google Scholar 

  36. Sonnichsen N, Meffert H, Kunzelmann V, Audring H. UV-A-1 therapy of subacute cutaneous lupus erythematosus. Hautarzt. 1993;44(11):723–5.

    PubMed  CAS  Google Scholar 

  37. McGrath Jr H. Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 1994;12(2):129–35.

    PubMed  Google Scholar 

  38. McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340–400 nm) irradiation therapy in systemic lupus erythematosus. Lupus. 1996;5(4):269–74.

    PubMed  CAS  Google Scholar 

  39. Polderman MC, Huizinga TW, Le Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial. Ann Rheum Dis. 2001;60(2):112–5.

    PubMed  CAS  Google Scholar 

  40. Fai D, Romano I, Cassano N, Vena GA. Cutaneous lupus erythematosus of the scalp treated with methyl-aminolevulinate photodynamic therapy: a case report. G Ital Dermatol Venereol. 2012;147(2):213–4. R23124243 [pii].

    PubMed  CAS  Google Scholar 

  41. Romero-Mate A, Castano-Suarez E, Garcia-Donoso C, Martinez-Moran C, Meseguer-Yebra C, Borbujo J. Unsuccessful treatment of recalcitrant cutaneous discoid lupus erythematosus with photodynamic therapy. Photodermatol Photoimmunol Photomed. 2010;26(3):156–8. doi:10.1111/j.1600-0781.2010.00506.x. PPP506 [pii].

    PubMed  CAS  Google Scholar 

  42. Fernandez-Guarino M, Perez-Garcia B, Harto A, Jaen P. Discoid lupus erythematosus: good response to treatment with photodynamic therapy. J Eur Acad Dermatol Venereol. 2008;22(9):1142–3. doi:10.1111/j.1468-3083.2007.02560.x. JDV2560 [pii].

    PubMed  CAS  Google Scholar 

  43. Morruzzi C, Liu V, Bohbot A, Cribier B, Lipsker D. Four cases of photopheresis treatment for cutaneous lupus erythematosus refractory to standard therapy. Ann Dermatol Venereol. 2009;136(12):861–7. doi:10.1016/j.annder.2009.10.183. S0151-9638(09)00614-0 [pii].

    PubMed  CAS  Google Scholar 

  44. Boeckler P, Liu V, Lipsker D. Extracorporeal photopheresis in recalcitrant lupus erythematosus. Clin Exp Dermatol. 2009;34(7):e295–6. doi:10.1111/j.1365-2230.2009.03239.x. CED3239 [pii].

    PubMed  CAS  Google Scholar 

  45. Richard MA, Saadallah S, Lefevre P, Poullin P, Buscaylet S, Grob JJ. Extracorporeal photochemotherapy in therapy-refractory subacute lupus. Ann Dermatol Venereol. 2002;129(8–9):1023–6. MDOI-AD-08-2002-129-8-9-0151-9638-101019-ART7 [pii].

    PubMed  CAS  Google Scholar 

  46. Sontheimer RD, Provost TT. Cutaneous manifestations of rheumatic diseases. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 318. xv.

    Google Scholar 

  47. Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr. 2000;137(5):674–80. doi:10.1067/mpd.2000.109108. S0022-3476(00)52765-6 [pii].

    PubMed  CAS  Google Scholar 

  48. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, Lee LA, Provost TT, Reichlin M, Rider L, Rupel A, Saleeb S, Weston WL, Skovron ML. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31(7):1658–66. S0735-1097(98)00161-2 [pii].

    PubMed  CAS  Google Scholar 

  49. Hornberger LK, Al Rajaa N. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol. 2010;72(3):189–97. doi:10.1111/j.1365-3083.2010.02437.x. SJI2437 [pii].

    PubMed  CAS  Google Scholar 

  50. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142(6):678–83. doi:10.1067/mpd.2003.233. S0022-3476(03)00178-1 [pii].

    PubMed  Google Scholar 

  51. Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics. 2002;109(1):E11.

    PubMed  Google Scholar 

  52. Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. 2011;20(11):1187–92. doi:10.1177/0961203311412096. 0961203311412096 [pii].

    PubMed  CAS  Google Scholar 

  53. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009;36(11):2539–46. doi:10.3899/jrheum.081141. jrheum.081141 [pii].

    PubMed  Google Scholar 

  54. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.

    PubMed  CAS  Google Scholar 

  55. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. 10.1002/1529-0131(199709)40:9 < 1725::AID-ART29 > 3.0.CO;2-Y.

    PubMed  CAS  Google Scholar 

  56. Ferraz MB, Goldenberg J, Hilario MO, Bastos WA, Oliveira SK, Azevedo EC, di Napoli D. Evaluation of the 1982 ARA lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology. Clin Exp Rheumatol. 1994;12(1):83–7.

    PubMed  CAS  Google Scholar 

  57. Huang JL, Lin CJ, Hung IJ, Luo SF. The morbidity and mortality associated with childhood onset systemic lupus erythematosus. Changgeng Yi Xue Za Zhi. 1994;17(2):113–20.

    PubMed  CAS  Google Scholar 

  58. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010;62(2):599–608. doi:10.1002/art.27218.

    PubMed  Google Scholar 

  59. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect. 2003;36(3):203–8.

    PubMed  Google Scholar 

  60. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550–6. doi:10.1016/j.jpeds.2007.09.019. S0022-3476(07)00875-X [pii].

    PubMed  Google Scholar 

  61. Sibbitt Jr WL, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, Bankhurst AD, Brooks WM. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29(7):1536–42.

    PubMed  Google Scholar 

  62. Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E. Longterm followup of childhood lupus nephritis. J Rheumatol. 2002;29(12):2635–42. 0315162X-29-2635 [pii].

    PubMed  Google Scholar 

  63. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–29. doi:10.1038/nrneph.2011.150. nrneph.2011.150 [pii].

    PubMed  CAS  Google Scholar 

  64. Ostensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2000;9(8):566–72.

    PubMed  CAS  Google Scholar 

  65. Levy ML, Barron KS, Eichenfield A, Honig PJ. Naproxen-induced pseudoporphyria: a distinctive photodermatitis. J Pediatr. 1990;117(4):660–4.

    PubMed  CAS  Google Scholar 

  66. Brunner HI, Klein-Gitelman MS, Ying J, Tucker LB, Silverman ED. Corticosteroid use in childhood-onset systemic lupus erythematosus-practice patterns at four pediatric rheumatology centers. Clin Exp Rheumatol. 2009;27(1):155–62. 2574 [pii].

    PubMed  CAS  Google Scholar 

  67. Niehues T, Lankisch P. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr Drugs. 2006;8(6):347–56. 863 [pii].

    PubMed  Google Scholar 

  68. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43(3):267–71. doi:10.1093/rheumatology/keh088. keh088 [pii].

    CAS  Google Scholar 

  69. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28. doi:10.1056/NEJMoa043731.

    PubMed  CAS  Google Scholar 

  70. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–40. doi:10.1093/rheumatology/kep346.

    Google Scholar 

  71. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD, Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285–96. doi:10.1002/art.30645.

    PubMed  CAS  Google Scholar 

  72. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, Hsu J, Klein-Gitelman M, Moorthy LN, Muscal E, Radhakrishna SM, Wagner-Weiner L, Adams M, Blier P, Buckley L, Chalom E, Chedeville G, Eichenfield A, Fish N, Henrickson M, Hersh AO, Hollister R, Jones O, Jung L, Levy D, Lopez-Benitez J, McCurdy D, Miettunen PM, Quintero-del Rio AI, Rothman D, Rullo O, Ruth N, Schanberg LE, Silverman E, Singer NG, Soep J, Syed R, Vogler LB, Yalcindag A, Yildirim-Toruner C, Wallace CA, Brunner HI, Carra SLES. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–83. doi:10.1002/acr.21558.

    Google Scholar 

  73. Gourley MF, Austin 3rd HA, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549–57.

    PubMed  CAS  Google Scholar 

  74. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33. doi:10.1002/art.27233.

    PubMed  CAS  Google Scholar 

  75. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, Group B-S. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30. doi:10.1002/art.30613.

    PubMed  CAS  Google Scholar 

  76. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80.

    PubMed  CAS  Google Scholar 

  77. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96. doi:10.1016/j.jaad.2008.05.005. S0190-9622(08)00591-4 [pii].

    PubMed  Google Scholar 

  78. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–50. doi:10.1001/archdermatol.2009.79. 145/5/545 [pii].

    PubMed  Google Scholar 

  79. Zulian F, Athreya BH, Laxer R, Nelson AM, de Oliveira SK F, Punaro MG, Cuttica R, Higgins GC, Van Suijlekom-Smit LW, Moore TL, Lindsley C, Garcia-Consuegra J, Esteves Hilario MO, Lepore L, Silva CA, Machado C, Garay SM, Uziel Y, Martini G, Foeldvari I, Peserico A, Woo P, Harper J. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614–20. doi:10.1093/rheumatology/kei251. kei251 [pii].

    CAS  Google Scholar 

  80. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13. doi:10.1097/01.bor.0000245727.40630.c3. 00002281-200611000-00007 [pii].

    PubMed  Google Scholar 

  81. Jue MS, Kim MH, Ko JY, Lee CW. Digital image processing for the acquisition of graphic similarity of the distributional patterns between cutaneous lesions of linear scleroderma and Blaschko’s lines. J Dermatol. 2011;38(8):778–83. doi:10.1111/j.1346-8138.2010.01162.x.

    PubMed  Google Scholar 

  82. Weibel L, Harper JI. Linear morphoea follows Blaschko’s lines. Br J Dermatol. 2008;159(1):175–81. doi:10.1111/j.1365-2133.2008.08647.x. BJD8647 [pii].

    PubMed  CAS  Google Scholar 

  83. Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, Koch A, Kostler E, Schonlebe J, Haroske G, Doede T, Pramatarov K. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extrem Wounds. 2007;6(4):291–8. doi:10.1177/1534734607308731. 6/4/291 [pii].

    PubMed  Google Scholar 

  84. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, Espada G, Corona F, Mukamel M, Vesely R, Musiej-Nowakowska E, Chaitow J, Ros J, Apaz MT, Gerloni V, Mazur-Zielinska H, Nielsen S, Ullman S, Horneff G, Wouters C, Martini G, Cimaz R, Laxer R, Athreya BH. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873–81. doi:10.1002/art.21264.

    PubMed  Google Scholar 

  85. Weibel L, Laguda B, Atherton D, Harper JI. Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol. 2011;165(6):1308–13. doi:10.1111/j.1365-2133.2011.10600.x.

    PubMed  CAS  Google Scholar 

  86. Mirsky L, Chakkittakandiyil A, Laxer RM, O’Brien C, Pope E. Relapse after systemic treatment in paediatric morphoea. Br J Dermatol. 2012;166(2):443–5. doi:10.1111/j.1365-2133.2011.10535.x.

    PubMed  CAS  Google Scholar 

  87. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006;155(5):1013–20. doi:10.1111/j.1365-2133.2006.07497.x. BJD7497 [pii].

    PubMed  CAS  Google Scholar 

  88. Johnson W, Jacobe H. Morphea in adults and children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment. J Am Acad Dermatol. 2012. doi:10.1016/j.jaad.2012.01.011. S0190-9622(12)00094-1 [pii].

    Google Scholar 

  89. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol. 2005;152(1):180–2. doi:10.1111/j.1365-2133.2004.06318.x. BJD6318 [pii].

    PubMed  CAS  Google Scholar 

  90. Stefanaki C, Stefanaki K, Kontochristopoulos G, Antoniou C, Stratigos A, Nicolaidou E, Gregoriou S, Katsambas A. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol. 2008;35(11):712–8. doi:10.1111/j.1346-8138.2008.00552.x. JDE552 [pii].

    PubMed  Google Scholar 

  91. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39(2 Pt 1):211–5. S0190-9622(98)70077-5 [pii].

    PubMed  CAS  Google Scholar 

  92. Pope E, Doria AS, Theriault M, Mohanta A, Laxer RM. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology. 2011;223(4):363–9. doi:10.1159/000335560. 000335560 [pii].

    PubMed  CAS  Google Scholar 

  93. de Rie MA, Enomoto DN, de Vries HJ, Bos JD. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology. 2003;207(3):298–301. doi:10.1159/000073093. 73093 [pii].

    PubMed  Google Scholar 

  94. Camacho NR, Sanchez JE, Martin RF, Gonzalez JR, Sanchez JL. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol. 2001;45(5):697–9. doi:10.1067/mjd.2001.117735. S0190-9622(01)19410-7 [pii].

    PubMed  CAS  Google Scholar 

  95. Gruss C, Reed JA, Altmeyer P, McNutt NS, Kerscher M. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet. 1997;350(9087):1295–6. S0140673697240444 [pii].

    PubMed  CAS  Google Scholar 

  96. Gruss CJ, Von Kobyletzki G, Behrens-Williams SC, Lininger J, Reuther T, Kerscher M, Altmeyer P. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed. 2001;17(4):149–55.

    PubMed  CAS  Google Scholar 

  97. Kerscher M, Volkenandt M, Gruss C, Reuther T, von Kobyletzki G, Freitag M, Dirschka T, Altmeyer P. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol. 1998;38(1):21–6. S0190-9622(98)70533-X [pii].

    PubMed  CAS  Google Scholar 

  98. Pereira N, Santiago F, Oliveira H, Figueiredo A. Low-dose UVA(1) phototherapy for scleroderma: what benefit can we expect? J Eur Acad Dermatol Venereol. 2011. doi:10.1111/j.1468-3083.2011.04137.x.

    Google Scholar 

  99. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440–7. doi:10.1016/j.jaad.2005.11.1063. S0190-9622(05)04607-4 [pii].

    PubMed  Google Scholar 

  100. Sator PG, Radakovic S, Schulmeister K, Honigsmann H, Tanew A. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol. 2009;60(5):786–91. doi:10.1016/j.jaad.2008.12.013. S0190-9622(08)02496-1 [pii].

    PubMed  Google Scholar 

  101. Stege H, Berneburg M, Humke S, Klammer M, Grewe M, Grether-Beck S, Boedeker R, Diepgen T, Dierks K, Goerz G, Ruzicka T, Krutmann J. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol. 1997;36(6 Pt 1):938–44. S0190-9622(97)80277-0 [pii].

    PubMed  CAS  Google Scholar 

  102. Wang F, Garza LA, Cho S, Kafi R, Hammerberg C, Quan T, Hamilton T, Mayes M, Ratanatharathorn V, Voorhees JJ, Fisher GJ, Kang S. Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy. Arch Dermatol. 2008;144(7):851–8. doi:10.1001/archderm.144.7.851. 144/7/851 [pii].

    PubMed  Google Scholar 

  103. Jacobe HT, Cayce R, Nguyen J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br J Dermatol. 2008;159(3):691–6. doi:10.1111/j.1365-2133.2008.08672.x. BJD8672 [pii].

    PubMed  CAS  Google Scholar 

  104. El-Mofty M, Mostafa W, El-Darouty M, Bosseila M, Nada H, Yousef R, Esmat S, El-Lawindy M, Assaf M, El-Enani G. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. Photodermatol Photoimmunol Photomed. 2004;20(3):148–56. doi:10.1111/j.1600-0781.2004.00081.x. PPP081 [pii].

    PubMed  CAS  Google Scholar 

  105. El-Mofty M, Mostafa W, Esmat S, Youssef R, Bousseila M, Nagi N, Shaker O, Abouzeid A. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed. 2004;20(2):93–100. doi:10.1111/j.1600-0781.2004.00080.x. PPP080 [pii].

    PubMed  CAS  Google Scholar 

  106. El-Mofty M, Zaher H, Bosseila M, Yousef R, Saad B. Low-dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed. 2000;16(2):43–9.

    PubMed  CAS  Google Scholar 

  107. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, Spieth K, Sachsenberg-Studer E, Kaufmann R, Podda M. PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol. 2000;43(4):675–8. doi:10.1067/mjd.2000.105503. S0190-9622(00)93869-6 [pii].

    PubMed  CAS  Google Scholar 

  108. Kerscher M, Meurer M, Sander C, Volkenandt M, Lehmann P, Plewig G, Rocken M. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol. 1996;132(11):1280–2.

    PubMed  CAS  Google Scholar 

  109. Li SC, Feldman BM, Higgins GC, Haines KA, Punaro MG, O’Neil KM. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol. 2010;37(1):175–81. doi:10.3899/jrheum.090708. jrheum.090708 [pii].

    PubMed  Google Scholar 

  110. Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Egla Rabinovich C, Laxer RM, Higgins GC, Lasky A, Baszis K, Becker M, Campillo S, Cartwright V, Cidon M, Inman CJ, Jerath R, O’Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC. Development of consensus treatment plans for juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012. doi:10.1002/acr.21687.

    Google Scholar 

  111. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycopcbrshenolate mofetil. Rheumatology (Oxford). 2009;48(11):1410–3. doi:10.1093/rheumatology/kep244. kep244 [pii].

    Google Scholar 

  112. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136(1):91–5. S0022-3476(00)90056-8 [pii].

    PubMed  CAS  Google Scholar 

  113. Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol. 2012;39(2):286–94. doi:10.3899/jrheum.110210. jrheum.110210 [pii].

    PubMed  CAS  Google Scholar 

  114. Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, Alessio M, Torre FL, Podda RA, Gerloni V, Cutrone M, Belloni-Fortina A, Paradisi M, Martino S, Perilongo G. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006. doi:10.1002/art.30264.

    PubMed  CAS  Google Scholar 

  115. Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E. Intravenous monthly high-dose pulse methylprednisolone vs oral prednisone for therapy of allergic bronchopulmonary aspergillosis in cystic fibrosis. Am J Respir Crit Care Med. 2009;179:A1184.

    Google Scholar 

  116. Falanga V, Medsger Jr TA. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol. 1990;126(5):609–12.

    PubMed  CAS  Google Scholar 

  117. Crespo MP, Mas IB, Diaz JM, Costa AL, Nortes IB. Rapid response to cyclosporine and maintenance with methotrexate in linear scleroderma in a young girl. Pediatr Dermatol. 2009;26(1):118–20. doi:10.1111/j.1525-1470.2008.00848.x. PDE848 [pii].

    Google Scholar 

  118. Strauss RM, Bhushan M, Goodfield MJ. Good response of linear scleroderma in a child to ciclosporin. Br J Dermatol. 2004;150(4):790–2. doi:10.1111/j.0007-0963.2004.05901.x. BJD5901 [pii].

    PubMed  CAS  Google Scholar 

  119. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257–63. doi:10.1016/j.jaad.2006.10.959. S0190-9622(06)03900-4 [pii].

    PubMed  Google Scholar 

  120. Hulshof MM, Bouwes Bavinck JN, Bergman W, Masclee AA, Heickendorff L, Breedveld FC, Dijkmans BA. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000;43(6):1017–23. S0190-9622(00)73612-7 [pii].

    PubMed  CAS  Google Scholar 

  121. Roldan R, Morote G, Castro Mdel C, Miranda MD, Moreno JC, Collantes E. Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children. J Rheumatol. 2006;33(12):2538–40. 0315162X-33-2538 [pii].

    PubMed  Google Scholar 

  122. Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol. 1980;116(2):169–73.

    PubMed  CAS  Google Scholar 

  123. Song P, Gocke C, Wigley FM, Boin F. Resolution of pansclerotic morphea after treatment with antithymocyte globulin. Nat Rev Rheumatol. 2009;5(9):513–6. doi:10.1038/nrrheum.2009.159. nrrheum.2009.159 [pii].

    PubMed  CAS  Google Scholar 

  124. Maragh SH, Davis MD, Bruce AJ, Nelson AM. Disabling pansclerotic morphea: clinical presentation in two adults. J Am Acad Dermatol. 2005;53(2 Suppl 1):S115–9. doi:10.1016/j.jaad.2004.10.881. S0190962204038721 [pii].

    PubMed  Google Scholar 

  125. Wollina U, Buslau M, Weyers W. Squamous cell carcinoma in pansclerotic morphea of childhood. Pediatr Dermatol. 2002;19(2):151–4. 0033 [pii].

    PubMed  Google Scholar 

  126. Scharffetter-Kochanek K, Goldermann R, Lehmann P, Holzle E, Goerz G. PUVA therapy in disabling pansclerotic morphoea of children. Br J Dermatol. 1995;132(5):830–1.

    PubMed  CAS  Google Scholar 

  127. Gruss C, Stucker M, Kobyletzki G, Schreiber D, Altmeyer P, Kerscher M. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol. 1997;136(2):293–4.

    PubMed  CAS  Google Scholar 

  128. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after - what do we really know? Report of 11 patients and review of the literature. Dermatology. 2006;213(2):93–101. doi:10.1159/000093847. 93847 [pii].

    PubMed  Google Scholar 

  129. Grisanti MW, Moore TL, Osborn TG, Haber PL. Eosinophilic fasciitis in children. Semin Arthritis Rheum. 1989;19(3):151–7. 0049-0172(89)90027-9 [pii].

    PubMed  CAS  Google Scholar 

  130. Huppke P, Wilken B, Brockmann K, Sattler B, Hanefeld F. Eosinophilic fasciitis leading to painless contractures. Eur J Pediatr. 2002;161(10):528–30. doi:10.1007/s00431-002-1038-1.

    PubMed  Google Scholar 

  131. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988;17(4):221–31.

    PubMed  CAS  Google Scholar 

  132. Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA, Verronen PM. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol. 1994;21(11):2143–6.

    PubMed  CAS  Google Scholar 

  133. Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, Lehman TJ, de Oliveira SK, Susic G, Lyskina G, Nemcova D, Sundel R, Falcini F, Girschick H, Lotito AP, Buoncompagni A, Sztajnbok F, Al-Mayouf SM, Orban I, Ferri C, Athreya BH, Woo P, Zulian F. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971–8. doi:10.1002/art.22207.

    PubMed  CAS  Google Scholar 

  134. Foeldvari I, Zhavania M, Birdi N, Cuttica RJ, de Oliveira SH, Dent PB, Elborgh R, Falcini F, Ganser G, Girschick H, Hafner R, Joos R, Kuis W, Pelkonen P, Prieur AM, Rostropowicz-Denisiewicz K, Russo R, Savolainen A, Siamopoulou-Mayridou A, Zulian F. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford). 2000;39(5):556–9.

    CAS  Google Scholar 

  135. Zulian F, Woo P, Athreya BH, Laxer RM, Medsger Jr TA, Lehman TJ, Cerinic MM, Martini G, Ravelli A, Russo R, Cuttica R, de Oliveira SK, Denton CP, Cozzi F, Foeldvari I, Ruperto N. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203–12. doi:10.1002/art.22551.

    PubMed  Google Scholar 

  136. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino Jr AV, Steen VD, Medsger Jr TA. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004–13. 06/13/044 [pii].

    PubMed  Google Scholar 

  137. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8. doi:10.1136/ard.2008.096677. ard.2008.096677 [pii].

    PubMed  CAS  Google Scholar 

  138. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44(8):1841–7. 10.1002/1529-0131(200108)44:8 < 1841::AID-ART322 > 3.0.CO;2-8.

    PubMed  CAS  Google Scholar 

  139. Marasini B, Massarotti M, Bottasso B, Coppola R, Papa ND, Maglione W, Comina DP, Maioli C. Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004;33(4):253–6. doi:10.1080/03009740310004711. XF1PLR3CT2H6AKAW [pii].

    PubMed  CAS  Google Scholar 

  140. Hummers LK, Wigley FM. Management of Raynaud’s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am. 2003;29(2):293–313.

    PubMed  Google Scholar 

  141. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger Jr TA, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32–8. doi:10.1136/ard.2010.130658. ard.2010.130658 [pii].

    PubMed  CAS  Google Scholar 

  142. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985–93. doi:10.1002/art.20676.

    PubMed  CAS  Google Scholar 

  143. Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford). 2010;49(3):583–7. doi:10.1093/rheumatology/kep413. kep413 [pii].

    CAS  Google Scholar 

  144. Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud’s phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford). 2006;45 Suppl 3:iii45–8. doi:10.1093/rheumatology/kel290. 45/suppl_3/iii45 [pii].

    CAS  Google Scholar 

  145. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PL. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73(4):372–82.

    PubMed  CAS  Google Scholar 

  146. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324–34. doi:10.1161/CIRCULATIONAHA.110.016667.

    PubMed  CAS  Google Scholar 

  147. Raja SG, Danton MD, MacArthur KJ, Pollock JC. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth. 2007;21(2):203–7. doi:10.1053/j.jvca.2006.02.010.

    PubMed  CAS  Google Scholar 

  148. Anderson ME, Moore TL, Hollis S, Jayson MI, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford). 2002;41(3):324–8.

    CAS  Google Scholar 

  149. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60(3):870–7. doi:10.1002/art.24351.

    PubMed  CAS  Google Scholar 

  150. Gargh K, Baildam EM, Cleary GA, Beresford MW, McCann LJ. A retrospective clinical analysis of pharmacological modalities used for symptomatic relief of Raynaud’s phenomenon in children treated in a UK paediatric rheumatology centre. Rheumatology (Oxford). 2010;49(1):193–4. doi:10.1093/rheumatology/kep309.

    Google Scholar 

  151. Teh LS, Manning J, Moore T, Tully MP, O’Reilly D, Jayson MI. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol. 1995;34(7):636–41.

    PubMed  CAS  Google Scholar 

  152. Kan C, Akimoto S, Abe M, Okada K, Ishikawa O. Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. Ann Rheum Dis. 2002;61(2):177–9.

    PubMed  CAS  Google Scholar 

  153. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009;36(2):323–9. doi:10.3899/jrheum.071169.

    PubMed  Google Scholar 

  154. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O’Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–8. 10.1002/1529-0131(200106)44:6 < 1351::AID-ART227 > 3.0.CO;2-I.

    PubMed  CAS  Google Scholar 

  155. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364–72.

    PubMed  Google Scholar 

  156. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66. doi:10.1056/NEJMoa055120.

    PubMed  CAS  Google Scholar 

  157. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G, Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026–34. doi:10.1164/rccm.200702-326OC.

    PubMed  CAS  Google Scholar 

  158. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012. doi:10.3899/jrheum.111229.

    PubMed  Google Scholar 

  159. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011;70(6):1104–7. doi:10.1136/ard.2010.142000.

    PubMed  CAS  Google Scholar 

  160. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford). 2009;48(12):1595–9. doi:10.1093/rheumatology/kep295.

    CAS  Google Scholar 

  161. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25(2):205–12. doi:10.1007/s10067-005-1157-y.

    PubMed  CAS  Google Scholar 

  162. Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35(6):1064–72.

    PubMed  CAS  Google Scholar 

  163. Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, Melchiorre D, Sapir T, Blank M, Shoenfeld Y, Pignone AM, Cerinic MM. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis. 2007;66(7):977–9. doi:10.1136/ard.2006.060111.

    PubMed  CAS  Google Scholar 

  164. Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, Tamaki K. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol. 2007;156(5):1058–60. doi:10.1111/j.1365-2133.2007.07777.x.

    PubMed  CAS  Google Scholar 

  165. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, Generini S, Matucci Cerinic M, Shoenfeld Y. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50(3):1005–7. doi:10.1002/art.20195.

    PubMed  Google Scholar 

  166. Dau PC, Callahan JP. Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol. 1994;70(2):159–65.

    PubMed  CAS  Google Scholar 

  167. Akesson A, Wollheim FA, Thysell H, Gustafson T, Forsberg L, Pahlm O, Wollmer P, Akesson B. Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis. Scand J Rheumatol. 1988;17(5):313–23.

    PubMed  CAS  Google Scholar 

  168. Dau PC, Kahaleh MB, Sagebiel RW. Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum. 1981;24(9):1128–36.

    PubMed  CAS  Google Scholar 

  169. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193–7. doi:10.1136/ard.2008.095463.

    PubMed  CAS  Google Scholar 

  170. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S17–22.

    PubMed  Google Scholar 

  171. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578–83. doi:10.1002/art.24249.

    PubMed  Google Scholar 

  172. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271–80. doi:10.1093/rheumatology/kep093.

    CAS  Google Scholar 

  173. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. doi:10.1186/ar2965.

    PubMed  Google Scholar 

  174. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70(6):1003–9. doi:10.1136/ard.2010.143974.

    PubMed  CAS  Google Scholar 

  175. Tamaki Z, Asano Y, Hatano M, Yao A, Kawashima T, Tomita M, Kinugawa K, Nagai R, Sato S. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol. 2012;22(1):94–9. doi:10.1007/s10165-011-0472-1.

    PubMed  CAS  Google Scholar 

  176. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63(11):3540–6. doi:10.1002/art.30548.

    PubMed  CAS  Google Scholar 

  177. Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, Seney S, Summers K. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63(11):3547–51. doi:10.1002/art.30549.

    PubMed  CAS  Google Scholar 

  178. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, Pachman LM. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–5. doi:10.1002/art.11122.

    PubMed  Google Scholar 

  179. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34(8):732–6.

    PubMed  CAS  Google Scholar 

  180. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28(4):833–57.

    PubMed  CAS  Google Scholar 

  181. Quinter SD, Chiu YE, Lyon VB, Holland KE, Ruggeri SY, Drolet BA. Inverse Gottron’s papules: an unusual cutaneous manifestation of juvenile dermatomyositis. Pediatr Dermatol. 2011. doi:10.1111/j.1525-1470.2011.01585.x.

    PubMed  Google Scholar 

  182. Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA, Chanoine JP, Petty RE. Lipodystrophy in patients with juvenile dermatomyositis–evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28(3):610–5.

    PubMed  CAS  Google Scholar 

  183. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637–44. doi:10.1111/j.1365-2133.2007.08055.x. BJD8055 [pii].

    PubMed  CAS  Google Scholar 

  184. Walling HW, Gerami P, Sontheimer RD. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management. Paediatr Drugs. 2010;12(1):23–34. doi:10.2165/10899380-000000000-00000. 3 [pii].

    PubMed  Google Scholar 

  185. Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed. 2004;20(5):230–4. doi:10.1111/j.1600-0781.2004.00115.x. PPP115 [pii].

    PubMed  CAS  Google Scholar 

  186. Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol. 1994;131(2):205–8.

    PubMed  CAS  Google Scholar 

  187. Sayre RM, Dowdy JC, Poh-Fitzpatrick M. Dermatological risk of indoor ultraviolet exposure from contemporary lighting sources. Photochem Photobiol. 2004;80:47–51. doi:10.1562/2004-02-03-RA-074.1. 2004-02-03-RA-074 [pii].

    PubMed  CAS  Google Scholar 

  188. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004;15(1):35–9. doi:10.1080/09541440042000269. E3J7403TVXYLMV62 [pii].

    PubMed  CAS  Google Scholar 

  189. Kim JE, Jeong MG, Lee HE, Ko JY, Ro YS. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol. 2011;23(3):348–51. doi:10.5021/ad.2011.23.3.348.

    PubMed  Google Scholar 

  190. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16(12):1545–7.

    PubMed  CAS  Google Scholar 

  191. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol. 2005;141(7):855–9. doi:10.1001/archderm.141.7.855. 141/7/855 [pii].

    PubMed  CAS  Google Scholar 

  192. Bloom BJ, Tucker LB, Klein-Gitelman M, Miller LC, Schaller JG. Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J Rheumatol. 1994;21(11):2171–2.

    PubMed  CAS  Google Scholar 

  193. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877–80. doi:10.1093/rheumatology/ken074. ken074 [pii].

    CAS  Google Scholar 

  194. Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol. 1988;124(11):1721–2.

    PubMed  CAS  Google Scholar 

  195. Nakagawa T, Takaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol. 1993;20(9):558–60.

    PubMed  CAS  Google Scholar 

  196. Wananukul S, Pongprasit P, Wattanakrai P. Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol. 1997;38(4):202–5.

    PubMed  CAS  Google Scholar 

  197. Skuterud E, Sydnes OA, Haavik TK. Calcinosis in dermatomyositis treated with probenecid. Scand J Rheumatol. 1981;10(2):92–4.

    PubMed  CAS  Google Scholar 

  198. Eddy MC, Leelawattana R, McAlister WH, Whyte MP. Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J Clin Endocrinol Metab. 1997;82(11):3536–42.

    PubMed  CAS  Google Scholar 

  199. Harel L, Harel G, Korenreich L, Straussberg R, Amir J. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol. 2001;28(5):1129–32.

    PubMed  CAS  Google Scholar 

  200. Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol. 2006;33(8):1691–3. 0315162X-33-1691 [pii].

    PubMed  Google Scholar 

  201. Jiang X, Yi Q, Liu D, Wang S, Li L. A case of juvenile dermatomyositis with severe calcinosis and successful treatment with prednisone and diltiazem. Int J Dermatol. 2011;50(1):74–7. doi:10.1111/j.1365-4632.2009.04449.x.

    PubMed  Google Scholar 

  202. Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol. 2001;144(4):894–7. 4153 [pii].

    PubMed  CAS  Google Scholar 

  203. Oliveri MB, Palermo R, Mautalen C, Hubscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23(12):2152–5.

    PubMed  CAS  Google Scholar 

  204. Bertorini TE, Sebes JI, Palmieri GM, Igarashi M, Horner LH. Diltiazem in the treatment of calcinosis in juvenile dermatomyositis. J Clin Neuromuscul Dis. 2001;2(4):191–3. 00131402-200106000-00005 [pii].

    PubMed  CAS  Google Scholar 

  205. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763–6. doi:10.1067/mpd.2001.112473. S0022-3476(01)76748-0 [pii].

    PubMed  CAS  Google Scholar 

  206. Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005;32(9):1837–9. 0315162X-32-1837 [pii].

    PubMed  Google Scholar 

  207. Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28(1):135–40. 254 [pii].

    PubMed  CAS  Google Scholar 

  208. Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine. 2010;77(1):70–2. doi:10.1016/j.jbspin.2009.04.011. S1297-319X(09)00208-5 [pii].

    PubMed  Google Scholar 

  209. Fuchs D, Fruchter L, Fishel B, Holtzman M, Yaron M. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol. 1986;5(4):527–30.

    PubMed  CAS  Google Scholar 

  210. Taborn J, Bole GG, Thompson GR. Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann Intern Med. 1978;89(5 Pt 1):648–9.

    PubMed  CAS  Google Scholar 

  211. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB, Ota S, Pilkington C, Reed AM, Scuccimarri R, Feldman BM. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953–61. doi:10.3899/jrheum.090953. jrheum.090953 [pii].

    PubMed  CAS  Google Scholar 

  212. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010;62(2):219–25. doi:10.1002/acr.20071.

    CAS  Google Scholar 

  213. Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second childhood arthritis and rheumatology research alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64(4):546–53. doi:10.1002/acr.20695.

    Google Scholar 

  214. Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol. 1996;23(8):1424–7.

    PubMed  CAS  Google Scholar 

  215. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491–6. doi:10.1093/rheumatology/keh082. keh082 [pii].

    CAS  Google Scholar 

  216. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27(11):1469–71. doi:10.1007/s10067-008-0973-2.

    PubMed  Google Scholar 

  217. Dagher R, Desjonqueres M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, Guiguonis V, Picherot G, Cimaz R. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711–6. doi:10.1007/s00296-010-1653-5.

    PubMed  Google Scholar 

  218. Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol. 2011;147(7):831–5. doi:10.1001/archdermatol.2011.49. archdermatol.2011.49 [pii].

    PubMed  Google Scholar 

  219. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, Guigonis V, Pagnier A, Brochard K, Sibilia J, Gottenberg JE, Bodemer C. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40. doi:10.3899/jrheum.101321. jrheum.101321 [pii].

    PubMed  CAS  Google Scholar 

  220. Silverman E, Eddy A. Chapter 21: Systemic lupus erythematosus. In: Textbook of pediatric rheumatology. 6th ed. Philadelphia: Elsevier; 2011. p. 318. Section 3.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Dermatology and Pediatrics, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI, 53226, USA

    Yvonne E. Chiu MD

  2. Department of Pediatrics, Levine Children’s Hospital/Carolinas Medical Center, 1000 Blythe Blvd, Charlotte, NC, 28203, USA

    Sheetal S. Vora MD, MS

  3. Department of Pediatrics, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada

    Ronald M. Laxer MDCM, FRCPC & Elena Pope MD, MSc

Authors
  1. Yvonne E. Chiu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheetal S. Vora MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald M. Laxer MDCM, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elena Pope MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvonne E. Chiu MD .

Editor information

Editors and Affiliations

  1. Pediatric & Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA

    Wynnis L. Tom

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Chiu, Y.E., Vora, S.S., Laxer, R.M., Pope, E. (2014). Connective Tissue Disease. In: Tom, W. (eds) Severe Skin Diseases in Children. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39532-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39532-1_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39531-4

  • Online ISBN: 978-3-642-39532-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation